AOD-9604

★ 73

Anti-Obesity Drug 9604 (HGH fragment 176-191)

HGH fragment — fat loss without GH side effects

Fat Loss

Half-life

~30 minutes (SubQ)

Route

SubQ

Cycle

Long cycles tolerated

Status

Phase 2b human trials completed (Metabolic Pharmaceuticals); did not advance to Phase 3. TGA-approved for compounding in Australia.

About

A 16-amino-acid fragment of HGH that retains the fat-burning action of growth hormone without the muscle-growth or blood-sugar effects. Reached Phase 2b trials by Metabolic Pharmaceuticals.

Mechanism

Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage) by activating β3-adrenergic receptors in adipocytes; does not affect IGF-1 or blood glucose.

Dosage

beginner

Amount: 250 mcg
Frequency: 1x per day on empty stomach
Route: Subcutaneous (SubQ)
Duration: 8-12 weeks

standard

Amount: 300-500 mcg
Frequency: 1x per day in the morning
Route: SubQ
Duration: 12-16 weeks

advanced

Amount: 500-1000 mcg
Frequency: Split AM + PM (empty stomach)
Route: SubQ
Duration: 12-16 weeks

Timing

Best on an empty stomach in the morning. Avoid food for 90 min after to maximize lipolysis.

Cycle structure

Long cycles tolerated — 12-16 weeks on, 4 weeks off. Receptor desensitization is minimal.

Reconstitution & Storage

5 mg + 2 mL → 2500 mcg/mL

Standard reconstitution. Often stacked with GH secretagogues for synergistic fat loss.

Lyophilized: freezer. Reconstituted: 2-8°C, 28 days.

Benefits

• Visceral and abdominal fat reduction
• No effect on blood glucose or insulin
• No effect on IGF-1 (safer for cancer history)
• Joint-friendly (unlike full GH)
• Well tolerated in clinical trials

Side effects

• Generally very mild
• Occasional injection-site irritation
• Mild fatigue first week
• No reported serious side effects in trials

Contraindications

• Pregnancy and breastfeeding (limited data)
• Eating disorder history (caution with intentional fat loss)

Gender notes

Men

Same dosing. Popular for stubborn belly fat after age 40.

Women

Same dosing. Particularly effective for post-menopausal abdominal fat.

Research

Ng FM et al: Lipolytic and antilipogenic actions of HGH fragment 177-191 ↗
Original characterization of the HGH 176-191 fragment's fat-burning mechanism.

Hormone and Metabolic Research · 2000
Heffernan M et al: AOD-9604 Phase 2 obesity trial ↗
12-week Phase 2 trial in obesity; modest but consistent fat loss without GH side effects.

Diabetes, Obesity and Metabolism · 2007

Stacks well with

CJC-1295 IPAMORELIN TESAMORELIN BPC-157

Track AOD-9604 doses in the app

Built-in reconstitution calculator, dose log, and reminders. Free on Android.

Get on Google Play

Educational use only. Not medical advice. Many peptides shown are not FDA-approved and remain research compounds. Always consult a qualified healthcare provider.